|
20-12-2024 11:09 EST
| ALK – Financial calendar for the 2025 financial year |
|
18-12-2024 6:52 EST
| Positive results advance peanut tablet to phase II development |
|
12-12-2024 10:06 EST
| ACARIZAX® approved in Europe for treatment of young children |
|
27-11-2024 7:46 EST
| ALK’s pivotal phase 3 trial in children published in reputable scientific journal |
|
14-11-2024 1:30 EST
| Nine-month interim report (Q3) 2024 (unaudited) |
|
9-11-2024 17:30 EST
| ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) |
|
7-11-2024 6:09 EST
| Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024 |
|
27-8-2024 11:30 EDT
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
22-8-2024 11:49 EDT
| Six-month interim report (Q2) 2024 |
|
22-8-2024 11:38 EDT
| ALK upgrades its full-year revenue and earnings outlook |
|
14-8-2024 5:58 EDT
| Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024 |
|
21-6-2024 12:43 EDT
| ALK upgrades its full-year revenue and earnings outlook |
|
21-6-2024 12:39 EDT
| ALK provides update on regulatory process for the house dust mite allergy tablet in China |
|
3-6-2024 12:02 EDT
| ALK launches new growth strategy and 2028 financial ambitions |
|
3-6-2024 1:00 EDT
| ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies |
|
30-5-2024 7:45 EDT
| ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review |
|
29-5-2024 4:57 EDT
| Listen in on ALK’s Capital Markets Day on 4 June 2024 |
|
2-5-2024 13:43 EDT
| Three-month interim report (Q1) 2024 (unaudited) |
|
2-5-2024 13:26 EDT
| ALK upgrades its full-year revenue outlook |
|
24-4-2024 10:35 EDT
| Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024 |
|
3-4-2024 9:40 EDT
| Grant of share-based long-term incentive instruments to members of the Board of Management and key employees |
|
26-3-2024 9:00 EDT
| Save the date for ALK’s Capital Markets Day on 4 June 2024 |
|
14-3-2024 12:40 EDT
| Annual General Meeting in ALK-Abelló A/S held on 14 March 2024 |
|
5-3-2024 10:45 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
4-3-2024 10:00 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
16-2-2024 8:00 EST
| Annual General Meeting in ALK-Abelló A/S on 14 March 2024 |
|
12-2-2024 10:15 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
12-2-2024 5:30 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
8-2-2024 7:35 EST
| Annual report 2023: ALK delivers 9% sales growth with profits up 50% |
|
7-2-2024 14:10 EST
| ALK and McMaster researchers discover new cell that remembers allergies |
|
5-2-2024 3:30 EST
| ALK’s 2030 CO2 reduction targets have been approved by SBTi |
|
31-1-2024 3:45 EST
| Release date of annual report 2023 for ALK and webcast |
|
25-1-2024 7:15 EST
| ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review |
|
18-1-2024 9:35 EST
| ALK completes first part of phase 1 trial with peanut SLIT-tablet |
